1 Pavlidis, N. & Pentheroudakis, G. Cancer of unknown primary site. Lancet Lond Engl379, 1428-1435, doi:10.1016/s0140-6736(11)61178-1 PMID - 22414598 (2012).
2 Rassy, E. & Pavlidis, N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol61, 139-141, doi:10.1016/j.canep.2019.06.006 PMID - 31254795 (2019).
3 Losa, F. et al. 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clin Transl Oncol20, 1361-1372, doi:10.1007/s12094-018-1899-z PMID - 29808414 (2018).
4 Ross, J. S. et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. Jama Oncol1, 40, doi:10.1001/jamaoncol.2014.216 PMID - 26182302 (2015).
5 Varghese, A. M. et al. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Ann Oncol28, 3015-3021, doi:10.1093/annonc/mdx545 PMID - 29045506 (2017).
6 Greco, F. A. Molecular Diagnosis of the Tissue of Origin in Cancer of Unknown Primary Site: Useful in Patient Management. Curr Treat Option On14, 634-642, doi:10.1007/s11864-013-0257-1 PMID - 23990214 (2013).
7 Rassy, E. & Pavlidis, N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol17, 541-554, doi:10.1038/s41571-020-0359-1 PMID - 32350398 (2020).
8 Hainsworth, J. D. et al. Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute. J Clin Oncol31, 217-223, doi:10.1200/jco.2012.43.3755 PMID - 23032625 (2012).
9 Moran, S. et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol17, 1386-1395, doi:10.1016/s1470-2045(16)30297-2 PMID - 27575023 (2016).
10 Hayashi, H. et al. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. J Clin Oncol37, 570-579, doi:10.1200/jco.18.00771 PMID - 30653423 (2019).
11 Fizazi, K. et al. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann Oncol30, v851, doi:10.1093/annonc/mdz394 (2019).
12 Rassy, E. et al. The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. Eur J Cancer127, 118-122, doi:10.1016/j.ejca.2019.12.016 PMID - 32007711 (2020).
13 Löffler, H., Puthenparambil, J., Hielscher, T., Neben, K. & Krämer, A. Patients With Cancer of Unknown Primary. Deutsches Aerzteblatt Online111, 481-487, doi:10.3238/arztebl.2014.0481 PMID - 25138727 (2014).
14 Pavlidis, N., Briasoulis, E., Hainsworth, J. & Greco, F. A. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer39, 1990-2005, doi:10.1016/s0959-8049(03)00547-1 (2003).
15 Mileshkin, L. et al. 519P Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study. Ann Oncol31, S459, doi:https://doi.org/10.1016/j.annonc.2020.08.629 (2020).
16 Erlander, M. G. et al. Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification. J Mol Diagnostics13, 493-503, doi:10.1016/j.jmoldx.2011.04.004 PMID - 21708287 (2011).
17 Meiri, E. et al. A Second‐Generation MicroRNA‐Based Assay for Diagnosing Tumor Tissue Origin. Oncol17, 801-812, doi:10.1634/theoncologist.2011-0466 PMID - 22618571 (2012).
18 National Comprehensive Cancer Network. Occult primary (Version 3.2020), <https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf> (2020).
19 Binder, C., Matthes, K. L., Korol, D., Rohrmann, S. & Moch, H. Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling. Cancer Med7, 4814-4824, doi:10.1002/cam4.1689 (2018).
20 Tothill, R. W. et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol231, 413-423, doi:10.1002/path.4251 (2013).
21 Gatalica, Z. et al. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget5, 12440-12447, doi:10.18632/oncotarget.2574 (2014).
22 Kato, S. et al. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res77, 4238-4246, doi:10.1158/0008-5472.Can-17-0628 (2017).
23 Chakravarty, D. et al. OncoKB: A Precision Oncology Knowledge Base. Jco Precis Oncol2017, 1-16, doi:10.1200/po.17.00011 PMID - 28890946 (2017).
24 Tothill, R. W. et al. Massively‐parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathology231, 413-423, doi:10.1002/path.4251 PMID - 24037760 (2013).
25 Lee, K. K. et al. 1888P Next-generation sequencing for better treatment strategy of cancer of unknown primary (CUP). Ann Oncol30, v766, doi:10.1093/annonc/mdz268.015 (2019).
26 Hayashi, H. et al. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site. Jama Oncol6, doi:10.1001/jamaoncol.2020.4643 PMID - 33057591 (2020).
27 R: A Language and Environment for Statistical Computing (Vienna, Austria 2020).